

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231, ON THE DATE INDICATED BELOW.



By: 

Date: Jan 27 2003

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Re: Patent Application of : Group Art Unit 1615  
Peter Watts :  
Conf. No.: 5106 :  
Appln. No. 09/749,152 : Examiner: Susan Tra  
Filed: December 27, 2000 :  
For: COLONIC DRUG DELIVERY : Attorney Docket  
COMPOSITION : No. 10774-21U1  
: (WESZ/P14089UA)  
: (P-0129)

RECEIVED  
FEB 03 2003  
TECH CENTER 1600/2900

**TERMINAL DISCLAIMER TRANSMITTAL LETTER**

Submitted herewith is a Terminal Disclaimer and Statement of Common Ownership with respect to the above-identified patent application.

<input checked="" type="checkbox"/>	A check in the amount of \$110.00 for the statutory disclaimer fee is enclosed herewith.
<input checked="" type="checkbox"/>	The Commissioner is hereby authorized to charge Deposit Account No. 50-1017 ( <b>Billing No. 210774.0022</b> ) as noted below. A duplicate copy is enclosed.
<input type="checkbox"/>	Statutory disclaimer fee in the amount of \$____.00.

01/31/2003 CNGUYEN 00000127 09749152

01 FC:1814

110.00 CP

☒ Any deficiencies or overpayments in the above-calculated fee.

Respectfully submitted,

PETER WATTS

27 January 2003  
(Date)

By:

Kristyne A. Bullock

KRISTYNE A. BULLOCK

Registration No. 42,371

**AKIN GUMP STRAUSS HAUER & FELD LLP**

One Commerce Square

2005 Market Street, Suite 2200

Philadelphia, PA 19103-7086

Telephone: 215-965-1200


**Direct Dial: 215-965-1348**

Facsimile: 215-965-1210

E-Mail: [kbullock@akingump.com](mailto:kbullock@akingump.com)

KAB:cmb  
Enclosures

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231, ON THE DATE INDICATED BELOW.



BY: 

DATE: Jan 27, 2003

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re.: Patent Application of  
Peter Watts

Conf. No.: 5106

Appln. No.: 09/749,152

Filed: December 27, 2000

Title: COLONIC DRUG DELIVERY  
COMPOSITION

:  
: Group Art Unit: 1615  
:  
: Examiner: Susan Tra  
:  
: Attorney Docket  
: No. 10774-21U1  
: (WESZ/P14089U1)  
: (P-0129)

TECH CENTER 1600/2900

FEB 03 2003

RECEIVED

#19

TERMINAL DISCLAIMER AND STATEMENT OF COMMON OWNERSHIP

In accordance with 37 C.F.R. § 1.321(b), Petitioner, West Pharmaceuticals Drug Delivery & Clinical Research Centre Limited, having a place of business at Albert Einstein Centre, Highfields Science Park, Nottingham, UK NG1 2TN represents that it is assignee of the whole and entire right, title and interest in and to the above-identified application, which is a continuation of prior U.S. Patent No. 6,228,396 (the "prior patent").

The prior patent was assigned to Petitioner by an Assignment recorded February 1, 2000, at Reel 010567, Frame 0980 by a prior assignee, Danbiosyst UK Limited, who had been assigned the above identified application by an assignment from the inventor recorded February 10, 1997, at Reel 8439, Frame 0240.

The present application was assigned to Petitioner by an Assignment recorded February 1, 2002, at Reel 010567, Frame 0980. Based on a review of evidentiary documents relating to the chain of title from the original owner to Petitioner, the undersigned hereby certifies that to the best of her knowledge and belief, both the present application and the prior patent are commonly owned by Petitioner.

Petitioner hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the present application which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. § 154 to § 156 of the prior patent. Petitioner hereby agrees that any patent so granted on the present application shall be enforceable only for

and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the present application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, Petitioner does not disclaim any terminal part of any patent granted on the present application that would extend to the expiration date of the full statutory term defined in 35 U.S.C. § 154 to § 156 of the prior patent, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable or is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or is terminally disclaimed under 37 C.F.R. § 1.321, has all claims cancelled by a re-examination certificate, or is in any manner terminated prior to the expiration of its full statutory term.

The undersigned official of Petitioner is empowered to act on behalf of Petitioner.

Respectfully submitted,

**West Pharmaceuticals Drug Delivery & Clinical  
Research Centre Limited**

27 January 2003  
(Date)

By:

Kristyne A. Bullock  
**KRISTYNE A. BULLOCK**

Registration No. 42,371

**AKIN GUMP STRAUSS HAUER & FELD LLP**

One Commerce Square

2005 Market Street, Suite 2200

Philadelphia, PA 19103-7013

Telephone: 215-965-1200

**Direct Dial: 215-965-1348**

Facsimile: 215-965-1210

E-Mail: [kbullock@akingump.com](mailto:kbullock@akingump.com)

KAB:cmb